David S. Ege - 27 Oct 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role
Executive Vice President and Chief Technology Officer
Signature
/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
Issuer symbol
MCRB
Transactions as of
27 Oct 2022
Net transactions value
-$39,745
Form type
4
Filing time
31 Oct 2022, 19:37:25 UTC
Previous filing
06 Jul 2022
Next filing
07 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MCRB Common stock Award $0 +20,000 +63% $0.000000 51,746 27 Oct 2022 Direct F1
transaction MCRB Common stock Sale $39,745 -5,012 -9.7% $7.93 46,734 31 Oct 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Remarks:

Executive Vice President and Chief Technology Officer